Skip to main content

Table 1 Clinical characteristics of patients

From: Who would avoid severe adverse events from nasointestinal tube in small bowel obstruction? A matched case–control study

 

Before propensity matching

After propensity matching

Characteristics

Success group (n = 121)

Failure group (n = 85)

p

Success group (n = 68)

Failure group (n = 68)

p

Age, n (%)

  

0.043

  

0.864

  < 60y

51 (42.1)

48 (56.5)

 

34 (50.0)

33 (48.5)

 

  ≥ 60y

70 (57.9)

37 (43.5)

 

34 (50.0)

35 (51.5)

 

Gender, n (%)

  

0.956

  

1.000

 Female

38 (31.4)

27 (31.8)

 

19 (27.9)

19 (27.9)

 

 Male

83 (68.6)

58 (68.2)

 

49 (72.1)

49 (72.1)

 

BMI, n (%)

  

0.137

  

0.970

 18.5–23.9

100(82.6)

66(77.6)

 

58(85.3)

57(83.8)

 

  > 23.9

10 (8.3)

4 (4.7)

 

1 (1.5)

1 (1.5)

 

  < 18.5

11 (9.1)

15 (17.6)

 

9 (13.5)

10 (14.7)

 

Diabetes, n (%)

  

0.175

  

1.000

 None

100 (82.6)

76 (89.4)

 

60 (88.2)

60 (88.2)

 

 Yes

21 (17.4)

9 (10.6)

 

8 (11.8)

8 (11.8)

 

Hypertension, n (%)

0.579

  

1.000

  

 None

111 (91.7)

79 (92.9)

 

62 (91.2)

62 (91.2)

 

 Yes

10 (8.3)

6 (7.1)

 

6 (8.8)

6 (8.8)

 

Tumor, n (%)

  

 < 0.001

  

0.015

 None

107 (88.4)

57 (67.1)

 

58 (85.3)

46 (67.6)

 

 Yes

14 (11.6)

28 (32.9)

 

10 (14.7)

22 (32.4)

 

Remission, n (%)

 < 0.001

  

 < 0.001

  

 None

0 (0.0)

31 (36.5)

 

0 (0.0)

25 (36.8)

 

 Yes

121 (100.0)

54 (63.5)

 

68 (100.0)

43 (63.2)

 

Cl level, n (%)

  

0.005*

  

0.010*

 Normol (96–112)

102 (90.3)

57 (73.1)

 

56 (88.9)

42 (68.9)

 

 High (> 112)

1 (0.9)

3 (3.8)

 

0 (0.0)

3 (4.9)

 

 Low (< 96)

10 (8.8)

18 (23.1)

 

7 (11.1)

16 (26.2)

 

CD, n (%)

  

 < 0.001*

  

 < 0.001*

 1

119 (98.3)

50 (58.8)

 

67 (98.5)

40 (58.8)

 

 2

1 (0.8)

19 (22.4)

 

0 (0.0)

16 (23.5)

 

 3

1 (0.8)

2 (2.4)

 

1 (1.5)

1 (1.5)

 

 4

0 (0.0)

13 (15.3)

 

0 (0.0)

11 (16.2)

 

 5

0 (0.0)

0 (0.0)

 

0 (0.0)

0 (0.0)

 

SAE, n (%)

  

 < 0.001

  

0.001

 0

119 (98.3)

69 (81.2)

 

67 (98.5)

56 (82.4)

 

 1

2 (1.7)

16 (18.8)

 

1 (1.5)

12 (17.6)

 

Pneumonia, n (%)

0.001*

  

0.006*

  

 None

119 (98.3)

74 (87.1)

 

68 (100.0)

60 (88.2)

 

 Yes

2 (1.7)

11 (12.9)

 

0 (0)

8 (11.8)

 

Fees (¥)

29,129

65,541

0.002

26,991

67,030

 < 0.001

Length (days)

16 (± 12)

26 (± 14)

0.013

15 (± 13)

25 (± 14)

 < 0.001

BMI, (kg/m2)

20.31 (± 2.16)

20.94 (± 2.03)

0.035

20.22 (± 1.92)

20.43 (± 1.82)

0.518

NLR, (ratio)

7.97 (± 8.75)

12.68 (± 20.13)

0.046

7.47 (± 7.58)

13.05 (± 21.97)

0.052*

WBC, (109/L)

7.65 (± 4.25)

9.61 (± 7.32)

0.030*

7.58 (± 3.45)

9.13 (± 5.98)

0.071

Ne, (109/L)

5.92 (± 4.12)

7.90 (± 7.14)

0.024*

5.77 (± 3.28)

7.44 (± 5.95)

0.049

  1. Bold values indicate statistically significant
  2. CD Clavien–Dindo grading of surgical complication, SAE severe adverse event, Remission, abdominal pain or distension relieved after NITs insertion; Cl level, level of chloride ion; Length, hospitalization duration; NLR, neutrophils/lymphocytes after NITs insertion; WBC, white blood cells hemoglobin after NITs insertion; Ne, neutrophils after NITs insertion; PSM tolerance: 0.02
  3. All p values < 0.05 were considered statistically significant
  4. *Fisher’s precise test